Chen Wenlan, Wang Hong, Liang Cheng
School of Information Science and Engineering, Shandong Normal University, Jinan, 250358, China.
Brief Bioinform. 2023 Sep 20;24(5). doi: 10.1093/bib/bbad282.
Cancer heterogeneity has posed great challenges in exploring precise therapeutic strategies for cancer treatment. The identification of cancer subtypes aims to detect patients with distinct molecular profiles and thus could provide new clues on effective clinical therapies. While great efforts have been made, it remains challenging to develop powerful computational methods that can efficiently integrate multi-omics datasets for the task. In this paper, we propose a novel self-supervised learning model called Deep Multi-view Contrastive Learning (DMCL) for cancer subtype identification. Specifically, by incorporating the reconstruction loss, contrastive loss and clustering loss into a unified framework, our model simultaneously encodes the sample discriminative information into the extracted feature representations and well preserves the sample cluster structures in the embedded space. Moreover, DMCL is an end-to-end framework where the cancer subtypes could be directly obtained from the model outputs. We compare DMCL with eight alternatives ranging from classic cancer subtype identification methods to recently developed state-of-the-art systems on 10 widely used cancer multi-omics datasets as well as an integrated dataset, and the experimental results validate the superior performance of our method. We further conduct a case study on liver cancer and the analysis results indicate that different subtypes might have different responses to the selected chemotherapeutic drugs.
癌症异质性给探索精确的癌症治疗策略带来了巨大挑战。癌症亚型的识别旨在检测具有不同分子特征的患者,从而为有效的临床治疗提供新线索。尽管已经付出了巨大努力,但开发能够有效整合多组学数据集以完成该任务的强大计算方法仍然具有挑战性。在本文中,我们提出了一种名为深度多视图对比学习(DMCL)的新型自监督学习模型用于癌症亚型识别。具体而言,通过将重建损失、对比损失和聚类损失纳入一个统一框架,我们的模型同时将样本判别信息编码到提取的特征表示中,并在嵌入空间中很好地保留样本聚类结构。此外,DMCL是一个端到端框架,癌症亚型可以直接从模型输出中获得。我们将DMCL与从经典癌症亚型识别方法到最近开发的先进系统的八种替代方法在10个广泛使用的癌症多组学数据集以及一个综合数据集上进行比较,实验结果验证了我们方法的优越性能。我们进一步对肝癌进行了案例研究,分析结果表明不同亚型可能对所选化疗药物有不同反应。